The American Society of Retina Specialists (ASRS) reported six cases of occlusive retinal vasculitis post pegcetacoplan injection. The etiology remains unclear, with evolving patient outcomes. Pegcetacoplan, targeting complement factor 3 in drusen, was approved for geographic atrophy treatment. Trials showed low rates of intraocular inflammation but no retinal vasculitis. Apellis Pharmaceuticals is investigating the cases, emphasizing the importance of sterile practices during injection.
他の言語に翻訳
原文コンテンツから
www.medscape.com
抽出されたキーインサイト
by Richard Mark... 場所 www.medscape.com 07-18-2023
https://www.medscape.com/viewarticle/994508深掘り質問